Next: Genetic profiles on Facebook?

November 4, 2008

Project seeks volunteers to make their DNA profiles public for researchers

People may be thinking about genetic testing again, after reading recent press reports about the Personal Genome Project.

Late last month, the first few volunteers saw some of their genetic information made public on the Internet.

This effort seeks 100,000 volunteers willing to have their DNA sequenced, databased, and stored online, along with identifying medical and personal information, in order to speed the development of medical genomics.

For a quick brush-up on the pros and cons of reading your own gene map, the search term
risks genetic testing
offers some balanced reflections.

In some cases, diagnosis by history and examination has already given way to genetic testing. For instance, it’s now time to think “genotype first” when you see a child with a developmental issue, said an editorial in the New England Journal of Medicine a few weeks ago.

See what you can find by searching through the article categories with the search term “genetic testing”.

Evidence-based Articles

Scroll down first page of results for genetic testing to find a recent systematic review in JAMA about genetic testing for chronic adult diseases.

Practical Articles/News

This category holds a news article showing that an inconclusive genetic result can be as distressing as a positive one.

Patient Education

Scroll down here to find a Mayo Clinic blog for patients who may want to learn more about the topic on their own time.


Now you can breathe easier about COPD

October 21, 2008

Spiriva doesn’t slow COPD decline, but it really helps a lot anyway

Tiotropium (Spiriva) did not achieve the main study objective of lowering the rate of decline in forced expiratory volume (FEV1) among COPD patients in the large multicenter UPLIFT trial.

However, the drug was responsible for significant improvements in

* lung function,
* quality of life, and
* time to first exacerbation

Patients in the study were allowed to use any respiratory medications they wanted, except for other inhaled anticholinergic agents.

Data from the same study just prompted the FDA to lift its earlier warning about tiotropium and the risk of stroke.

Like the TORCH study reported earlier this year, the UPLIFT study came close to (but did not succeed in) finding a significant effect on mortality.

The best way to slow the rate of FEV1 decline, of course, is to quit smoking. This helps even patients with severe COPD, according to a new review in the European Respiratory Journal.

Research/Reviews

In this category, you’ll find the latest research into the predictive value of the BODE index in COPD.

Related searches

Find reports from earlier trials of interventions to slow the respiratory decline in COPD:

EUROSCOP

ISOLDE

BRONCUS


How not to eat your way to diabetes

August 12, 2008

Calories—not sugar, carbs, or fat—cause type 2 diabetes in those at risk

What people eat controls what they weigh, and that (setting aside genes and exercise) seems to determine the risk of type 2 diabetes—not the types of macronutrients themselves. That’s the upshot of two new studies in the Archives of Internal Medicine, according to a review in the same issue.

It’s not the sugar in soft drinks or juices but the poundage they so easily add that predisposes to type 2 diabetes, according to a study of young African-American women in the July 28 issue of Archives.

It was probably weight loss per se, not the low-fat or high-fiber diet, that reduced glycemia among postmenopausal women in the other study.

Which is best for weight loss: low carbs, low fat, or the Mediterranean diet? Depends on the patient’s underlying risk profile. The latter may be best for people at risk of diabetes, according to another new report, this one in the New England Journal of Medicine.

Related searches

Mediterranean diet diabetes

obesity children juice

menopause metabolic syndrome testosterone

Research/Reviews

How much exercise do patients need to maintain weight loss? Find more new reports in this article category.

Patient Education

Look in this category for trustworthy information for patients about physical activity and diabetes.


This news may make insomniacs of people with apnea

August 5, 2008

When MI complicates sleep apnea, it tends to strike in the wee hours

Onset of myocardial infarction in the middle of the night is significantly associated with obstructive sleep apnea (OSA), according to a new report in the Journal of the American College of Cardiology.

In a prospective study of 92 MI patients, those found to have sleep apnea were more than five times as likely to have had their coronary events between midnight and 6 AM.

Using SearchMedica’s new Practice Management tab (above the main search box), you can quickly find information about Medicare policy regarding OSA treatment.

Research/Reviews

Has CPAP been shown to have any effect on myocardial infarction in OSA? Find the latest here.

CME

Review the management of obstructive sleep apnea with a new online CME course.


Eluting stents cleared of death charge

July 8, 2008

Medicare claims show no added mortality risk from drug-eluting stents

Doctors at Dartmouth compared outcomes for people who had metal stents before the sirolimus-eluting stent became available with those for who later got the new stent called Cypher. There was virtually no difference in mortality, they report in the Journal of the American Medical Association.

As in prior studies, those who had the drug-eluting stent were less likely to need treatment for restenosis.

The drug-eluting stent certainly does no harm, conclude the authors, who compared data from nearly 67,000 individuals given stents on a non-emergency basis.

But they didn’t study the paclitaxel-eluting stent (Taxus) and could not assess the possible influence of dual-antiplatelet therapy.

Related searches

STEMI stents

Taxus

Evidence-based Articles

What is the existing evidence about the best protocol for dual antiplatelet therapy in patients who are stented?

Research/Reviews

What is the risk of late thrombosis in stent recipients?

Practice Guidelines

What are current practice standards in use of drug-eluting stents?


Why hearts fail when they do

May 13, 2008

Multicenter trial defines predictors of heart failure admission, death

Renal failure and pneumonia are the most deadly comorbidities for heart-failure patients, either in the hospital or within 3 months post-discharge. These results come from OPTIMIZE-HF, the first large multicenter trial to pre-define predictors and outcomes in heart failure

Pneumonia, ischemia and arrhythmia were the most frequent factors precipitating hospital admission. Uncontrolled hypertension and nonadherence to diet or medication were less adverse factors.

Practice Guidelines
The report bolsters national heart failure guidelines that call for detecting and addressing precipitating factors in acute decompensated heart failure.

Clinical Trials
A description of OPTIMIZE-HF (and a complete clickable list of its related publications), is available from the government Clinical Trials directory available on SearchMedica category.

Related searches:

renal failure HF

pneumonia heart failure

arrhythmia HF

ischemia HF


OT Gives Stroke Patients Real Hope

October 11, 2007

A new meta-analysis finds that stroke patients function better in daily activities after they have specific occupational therapy (training in dressing, self-feeding and the like). The researchers say that this should advance the discussion beyond merely whether occupational therapy helps outcomes in stroke, to what kind of OT is best for these patients.

Previous systematic reviews about occupational therapy, they say, have not focused specifically on stroke (although you’ll find a Cochrane review by the same authors on the topic of stroke also published this year).

Clinical Trials for Patients
A look at current clinical trials suggests that this topic is not yet high on the research agenda.

Patient Education Materials
Quickly find an article for patients about what to expect during stroke recovery.


FDA Label-Change Aims to Personalize Fibrillation Treatment

August 30, 2007

In updating the package label for warfarin last week, the Food and Drug Administration alerted patients that genetic testing could be used customize their dosages. The agency said the change “highlights the opportunity” for doctors to use genetic testing when prescribing warfarin. But it offered no advice about how to do so.

Find the meta-analysis that prompted this decision. The studies show that patients with a few genetic types need less warfarin than most.

Refine your results into clinically useful categories:

Practical Articles and News
The FDA declined to recommend any particular warfarin dosing algorithm.

Clinical Trials for Patients
A clinical trial now underway compares pharmacogenomic dosing with a decision-model algorithm for warfarin dosing.

Patient Education Materials
It’s probably too soon to give your patients a brochure about gene testing and warfarin. But you can provide something that tells how you normally choose the dose.


CVD Is a Harbinger of Kidney Disease

June 28, 2007

It’s well known that kidney disease is a risk factor for cardiovascular disease. Now an analysis involving data from nearly 14,000 patients shows for the first time that cardiovascular disease is an independent risk factor for kidney function decline. The authors pooled results from two longitudinal studies, tracking serum creatinine and estimated glomerular filtration rate in patients with baseline cardiovascular disease over more than nine years.

An accompanying editorial declared that primary care physicians should screen heart patients for kidney disease routinely. This has not been common practice, surveys show.

Refine your search with clinically useful categories:

Practice Guidelines
Find the latest expert guidance about detecting chronic kidney disease in patients with cardiovascular disorders.

Practical Articles and News
What are the practical implications of this news on the matter of ACE inhibitors and renal function?


New Study Could End the Dream of Delaying Type 2 Diabetes

June 7, 2007

A Cleveland Clinic team brewed a storm when their meta-analysis of 42 placebo-controlled studies involving rosiglitazone turned up a significantly increased risk of myocardial infarction and an increase of “borderline significance” in cardiovascular deaths. An accompanying editorial in the New England Journal of Medicine questions whether the drug was approved and used too soon, on the basis of a mere secondary effect (lowering blood glucose). Another in the Lancet urges doctors to wait for further evidence before leaping to judgment.

Is this the letdown after a happy fantasy? Only six months ago, the results of the aptly named DREAM trial were prompting suggestions that the drug might prevent type 2 diabetes.

Refine your search with these clinically useful categories:

Practical Articles and News
In the news category, you can find the safety alert that the Food and Drug Administration swiftly issued in response to the new study.

Evidence-based Articles and Meta-analyses
Critics argue that the FDA approved the drug without sufficient evidence of benefit regarding primary outcomes such as mortality. What does evidence-based research show about the effects of rosiglitazone?

Clinical Trials for Patients
Learn what clinical trials now underway may provide new information about the use of this drug.